Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × lobaplatin × Clear all

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms